All News

RA is worst with temperature rising/ climate change. However SpA has the opposite effect! Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD

Links:

Bella Mehta bella_mehta ( View Tweet)
Tips for Dx RP: 1. Suspect the dx and recognize chondritis. 2. Rule out mimickers 3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA) 4. CV, heme, derm manifestations 🧐VEXAS. 5. biopsy not useful unless ≠ from GCA. Fantastic session by @Lupusreference https://t.co/W4DgfeRULF

Links:

Adela Castro AdelaCastro222 ( View Tweet)
#EULAR2025 Abstr#POS1155 Fatigue remains a management challenge in #SLE. Consistent with other endpoints achieved, Dapirolizumab+SOC improved fatigue (FACIT-Fatigue & FATIGUE-PRO) over PBO+SOC in a Phase 3 RCT @RheumNow https://t.co/rYujy2YjBl

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory? Rx Retro study 388 patients RA 18% at least one sign CPPD ns diff between seeonegative and seropositive pts RA+CPPD group was -older -higher comorbidity score -more likely to be https://t.co/DaW5DZoDzF

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk - Chikungunya - Dengue - Zika - West-Nile Virus @RheumNow #EULAR2025 https://t.co/HtHyADsOSX

Links:

Bella Mehta bella_mehta ( View Tweet)
Climate Change Impacts #Rheumatology Care Taking HEAT 🥵 causes: 🔺️⬆️ Hospitalisations 🔺️Renal failure ⚠️ NSAIDs 🔺️Flooding: no access to healthcare 🔺️New Infectious diseases mimics RMDs: Zika... 🔺️Insecurities for drug storage and transportation #EULAR2025 @RheumNow https://t.co/V9RyxYX6Me

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#GameChanger Subset analysis of #CTD Pts with Progressive pulmonary fibrosis #PPF Ok background #nintedanib 1/3 ❎lung IS 2 doses #PDE4Bi #nerandomilast vs #PBO each dose ⬇️worsening #FVC vs PBO ⬇️lung events - hospital ⬇️death GI A/E #EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN

Links:

Janet Pope Janetbirdope ( View Tweet)
Genicular artery embolisation is like so many interventions in MSK medicine: early promise with smaller RCT & observational data, but the later, more robust data doesn’t show the same benefit. If you do meta-analyses of all these data, you mix good with bad #EULAR2025 @RheumNow https://t.co/K1tN9KX8rq

Links:

David Liew drdavidliew ( View Tweet)
Management and prognosis of RP by @Lupusreference 1. Pts with mild disease respond to GCs 2. NSAIDs/colchicine good alternatives 3. Most common biologics used: TNFi and IL6i 4. Consider CYP in life threatening dz/ICU pts 5. Dynamic CT assess tracheal collapse. 6. PET-CT can ≠ https://t.co/PNUecMZvkT

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Results from open label extension of BE-OPTIMAL: -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y. -No significant major tolerability issues or major SE. abstract #POS1294 #EULAR2025 @RheumNow https://t.co/VAEiciCR1z

Links:

Adela Castro AdelaCastro222 ( View Tweet)
ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why? ICI-IA and ICI-PMR look different, but at @HSpecialSurgery, steroid needs and disease impact for both are basically the same. Let’s not devalue either @lovetolearn27 #EULAR2025 POS1200 @RheumNow https://t.co/NVq2tpjvdu

Links:

David Liew drdavidliew ( View Tweet)
#EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis. Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis #EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq

Links:

David Liew drdavidliew ( View Tweet)
Social disparities in rheumatology @RheumNow #EULAR2025 ~70% of outcomes are determined by Social determinants of health Modifiable factors ? Maybe? https://t.co/UfC2nQ5Azy

Links:

Bella Mehta bella_mehta ( View Tweet)
@RheumNow Achieving health equity is the goal 1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX

Links:

Bella Mehta bella_mehta ( View Tweet)
How much of the health outcomes are related to social determinants? 🔺️Up to 75%! Disaster Medicine Session Social disparities and impact on outcomes Dr Kate Webb #EULAR2025 @RheumNow https://t.co/0Ahbf79Nbx

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Low disease activity more difficult to achieve in vulnerable populations. All rheumatic diseases - #RA #PsA #AS initiating DMARDs takes longer in these population #EULAR2025 @RheumNow https://t.co/voIivshKRt

Links:

Bella Mehta bella_mehta ( View Tweet)
×